worldwide offices | contact | help | sitemap

 

 

 

 

Newsroom

Newsroom

Meningococcal Disease Press Kit

Global Press Releases

Novartis vaccine Bexsero approved in the US

Novartis Bexsero® vaccine approved by FDA for the prevention of meningitis B, a leading cause of bacterial meningitis in the US. Download Press Release (242 KB)

Novartis vaccine Bexsero approved in Australia

Novartis vaccine Bexsero® approved in Australia to help protect against MenB disease, a deadly form of bacterial meningitis. Download Press Release (204 KB)

 

 

US Press Releases

FDA expands age indication for Menveo

FDA expands age indication for Menveo®, first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age. Download Press Release (184 KB)


 

 

US Fact Sheets

US Bexsero Fact Sheet

US Menveo Fact Sheet

US Meningococcal Disease Fact Sheet

US Meningococcal Group B Fact Sheet

 

 

Global Fact Sheets

Bexsero Fact Sheet


 

 

General Fact Sheets

Meningococcal Disease Fact Sheet


Untold Toll of Meningococcal Disease Fact Sheet


Value of Vaccines Fact Sheet


 

 

Infographics

The Need to Know Facts About Invasive Meningococcal Disease

Meningococcal Disease: A Story by Numbers

Bexsero (Meningococcal Group B Vaccine) R&D Timeline

 

 

Videos

Bexsero B-Roll

Bexsero B-Roll

Meningococcal Disease Awareness

Meningococcal Disease Awareness

Protecting our Tomorrows

Protecting our Tomorrows

Meningitis Parents Story

Meningococcal Disease: A Parent's Story

 

 

US Images

US Bexsero Logo

US Bexsero Logo

All rights reserved.

US Bexsero Package Image

US Bexsero Package Image

All rights reserved.

US Menveo Logo

US Menveo Logo

All rights reserved.

US Menveo Package Image

US Menveo Package Image

All rights reserved.

 

 

General Images

Marshall Janson

Marshall Janson
Marshall was diagnosed with meningitis shortly after his first birthday. While he was lucky to survive, he lost both his hands and legs as a result of the infection. Prevention and responding to the signs of meningitis as quickly as possible are critical to reducing the impact of this devastating disease.
Read more about Marshall’s story ›

All Licensed Material used in an editorial context, must include the following credit line adjacent to the Licensed Material: "[Provided by Meningitis UK].”

Logane Miller

Logane Miller - image 1
Just before her first birthday, Logane contracted meningitis. After a week of battling the infection, Logane finally pulled through, but lost her right leg and left foot. Prevention and responding to the signs of meningitis as quickly as possible are critical to reducing the impact of this devastating disease.
Read more about Logane’s story ›

All Licensed Material used in an editorial context, must include the following credit line adjacent to the Licensed Material: "[Provided by Meningitis Research Foundation]."

Logane Miller

Logane Miller - image 2

All Licensed Material used in an editorial context, must include the following credit line adjacent to the Licensed Material: "[Provided by Meningitis Research Foundation]."

Physician, mother and infant 1

Physician, mother and infant - image 1

All rights reserved.

Physician, mother and infant 2

Physician, mother and infant - image 2

All rights reserved.

Infant being examined

Infant being examined

All rights reserved.

Andrew Meigs

Bexsero® US Vaccination Image 1
Meningococcal meningitis survivor and vaccination advocate Leslie Meigs looks on as her brother Andrew (18), a college student in Texas, receives Bexsero®, a meningococcal group B vaccine approved by the FDA for ages 10-25 in January. Meningococcal group B is one of the most prevalent types of meningococcal disease in the US, and adolescents and young adults are at risk due to common lifestyle habits such as living in college dormitories. Bexsero is approved to help protect against the potentially deadly disease in two doses, however is not expected to cover all group B strains. For more information visit www.Bexsero-US.com.

All Rights Reserved

Andrew Meigs

Bexsero® US Vaccination Image 2
Until recently, there was no vaccine available in the US to help protect against meningococcal group B, one of the most prevalent types of meningococcal meningitis in the US. Leslie Meigs, meningococcal meningitis survivor and vaccination advocate, joins her brother Andrew (18) as he receives vaccination with Bexsero®, a meningococcal group B vaccine approved by the FDA for ages 10-25 in January. Bexsero is administered in two doses to help protect against the devastating disease, however is not expected to cover all group B strains. Bexsero is approved in more than 36 countries. For more information visit www.Bexsero-US.com.

All Rights Reserved

 

 

Follow Us

 

About Novartis Vaccines

vaccines

Novartis Vaccines is the world's fifth-largest vaccines business.